Pfizer Inc. (NYSE:PFE) Shares Acquired by Stockman Wealth Management Inc.

Stockman Wealth Management Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 299,101 shares of the biopharmaceutical company’s stock after buying an additional 22,199 shares during the quarter. Pfizer makes up about 1.3% of Stockman Wealth Management Inc.’s investment portfolio, making the stock its 28th largest holding. Stockman Wealth Management Inc.’s holdings in Pfizer were worth $8,656,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in PFE. Olistico Wealth LLC acquired a new position in Pfizer in the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer in the second quarter worth $29,000. Quarry LP acquired a new position in Pfizer in the second quarter worth $31,000. Financial Connections Group Inc. acquired a new position in Pfizer in the second quarter worth $34,000. Finally, ESL Trust Services LLC acquired a new position in shares of Pfizer during the first quarter valued at $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Performance

PFE traded down $0.32 on Friday, hitting $26.72. The company had a trading volume of 55,951,315 shares, compared to its average volume of 37,583,031. The company’s fifty day moving average price is $28.89 and its 200 day moving average price is $28.63. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.60. The stock has a market cap of $151.42 billion, a price-to-earnings ratio of 36.11, a price-to-earnings-growth ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the company earned ($0.17) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.29%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.